Background: Type 2 diabetes mellitus (T2DM) affects diverse demographic populations, including resource-challenged (deserving) and rural communities.In India, managing T2DM often involves substantial out-of-pocket expenses, leading to significant health-related financial burdens. Therefore, Indian clinicians should consider affordable, cost-effective, and accessible oral antidiabetic agents (OADs) to optimize T2DM care. Aim: DESERVE INDIA CONSENSUS (Diligent Endeavor to Support Deserving T2DM Patients with Individualized Treatment Interventions for Resource-Challenged Settings in India) aimsto address the need for awareness and access to high-quality, affordable, cost-effective interventional approaches for effectively managing resource-challenged (deserving) T2DM patients in India. Methods: This mixed-methods study in India involved a quantitative survey of 590 clinicians and qualitative focus group discussions (FGDs) with 60 subject matter experts. The study was conducted between January and March 2024.A structured questionnaire was developed for quantitative data collection regarding clinician management approaches for patients with resource-challenged (deserving) T2DM.Four-day virtual FGDs with subject matter experts for consensus development were organized for qualitative data collection. Results: The 590 clinicians surveyed agreed with several critical statements regarding the efficacy, safety, and cost-effectiveness of the fixed-dose combination (FDC) of glipizide + metformin in managing resource-challenged (deserving) T2DM patients.Most clinicians (84.0%) agreed that glipizide + metformin FDC is a clinically preferred SU-based combination, as it has a lower risk of hypoglycemia due to its short half-life.A similar proportion of clinicians agreed that this combination is safe in patients with moderate-to-severe chronic kidney disease and can be used effectively in managing resource-challenged (deserving) T2DM patients.Nearly 65.08% of the clinicians agreed thatglipizide + metformin FDCcould be a first-line consideration in resource-challenged (deserving) T2DM patients.Approximately 90.0% of clinicians agreed that glipizide and metformin FDC, with a monthly cost of < 120 INR, are cost-effective interventions for resource-challenged (deserving) T2DM patients in India.Most (94.0%) cliniciansacknowledged their role in improving the outcomes of resource-challenged (deserving) T2DM patients by improving the awareness, access, availability, and affordability of high-quality medications. Conclusion: Indian clinicians favoured prescribing cost-effective OADs, such as glipizide + metformin FDC, as a first-line consideration to improve patient adherence and treatment outcomes in resource-challenged (deserving) T2DM patients.